Joerg Herrmann is a Cardiology physician affiliated with Mayo Clinic. OpenAlex indexes 365 publications with 17,966 citations (h-index 63); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Cardiovascular Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 1st St SW
Rochester, MN 559050001
Telephone
507-284-2511Provider last certified this registry record 14 Aug 2020.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- PFIZER INC.Program year20224 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
79.8%Aldosterone antagonist (MRA)30.6%Spironolactone100%Part D<11 patientsBeta blocker19.4%Carvedilol54%Nebivolol Hcl46%Part D<11 patients+ 2 more classes in this area
Blood & clotting
20.2%Factor Xa inhibitor20.2%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2014–2024 per NIH RePORTER. The latest:
- TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial
Mayo Clinic Rochester
FY2024$773,975R01CA233610 - TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial
Mayo Clinic Rochester
FY2023$798,417R01CA233610 - TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial
Mayo Clinic Rochester
FY2022$825,573R01CA233610
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Rick Nishimura, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”